Insud Pharma biotech subsidiary Mabxience has announced plans to add to its biosimilar production capacity as well as bolster its contract development and manufacturing business by investing in an expansion of its facility in León, Spain.
The firm said the expansion – in the form of an ABEC 4,000-liter single-use bioreactor – would use ABEC’s custom single run technology to increase
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?